ReviewJournal of cellular and molecular medicine2026
PACS2 at Mitochondria-Associated Membranes: A Central Regulator of Cardiovascular and Metabolic Diseases.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and metabolic diseases (CVMDs), which are characterized by metabolic dysregulation and cardiovascular impairment, constitute a major global cause of mortality, thus highlighting the urgent need for novel therapeutic strategies. Phosphofurin acidic cluster sorting protein 2 (PACS2), a multifunctional adapter protein localized to mitochondria-associated membranes (MAMs), regulates intracellular membrane trafficking and is pivotal for critical cellular processes, including apoptosis, autophagy and ferroptosis. Accumulating evidence implicates PACS2 dysregulation in the pathogenesis of diverse CVMDs, including metabolic disorders and cardiovascular conditions. This review examines the structural and functional basis of PACS2 and details its established and emerging roles in the pathogenesis of CVMDs. Collectively, these findings identify PACS2 as a crucial regulator of CVMD development and progression, underscoring its significant potential as both a diagnostic biomarker and a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.